Roth Capital Comments On Galena Biopharma As Herceptin Combo Starts As Expected
Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Galena Biopharma (NASDAQ:GALE) with an $8 price target, as the company announced the expected initiation of the Phase II combination with NeuVax and Herceptin.
Pantginis commented: “This additional Phase II NeuVax study is encouraging because of its potential to further broaden the addressable population by NeuVax in preventing recurrence. The key mechanism we look at NeuVax providing to this patient population is the expected ability to mop up residual disease and bring in an additional immune component beyond Herceptin.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -4.0% and a 45.4% success rate. Pantginis has a -23.7% average return when recommending GALE, and is ranked #3261 out of 3369 analysts.